Astellas Abandons Plans For Blood Clot Drug

BMI View: Despite Astellas's impressive focus on innovation and its rich cabinet of transplant and urology therapies in early development, the company's decision to stop darexaban mid-way through the process reiterates our long-standing view that it to face an ongoing risk of pipeline products failing to

To read the full article, please choose one of the following options: